Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-12-13 15:56 CET (UTC+1h)
 

Multiple dose study for MR product in EU [Regulatives / Guidelines]

posted by Samaya B - India, 2014-09-27 11:06  - Posting: # 13599
Views: 1,766

» "A multiple dose study is needed unless a single dose study has been performed with the highest strength which has demonstrated that the mean AUC(0-τ) after the first dose covers more than 90% of mean AUC(0-∞) for both test and reference, and consequently a low extent of accumulation is expected".
»
» Please elaborate or simplify the same for better understanding.

Dear Mahesh,

You can consider "first dose" as a "single dose" study.

For MR products in EMEA, first perform pivotal BE study under fasting state and evalaute the results. If AUC0-t>0.9*AUCinf, you need not to go ahead for steady state BE study. BE under steady state is required when drug accumulates in body. If AUC0-t> 0.9*AUCinf is achieved after signle dose administration, normally, there would not be accumulation.

You can refer following posts as well: #12612, #7062, #8296

Hope this info would be helpful.

Regards,
Samaya.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,556 Posts in 3,758 Threads, 1,089 registered users;
35 users online (0 registered, 35 guests).

The purpose of models is not to fit the data,
but to sharpen the questions.    Samuel Karlin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed